Engineered Oncolytic Virus Reprograms Immunity and Extends Survival in Brain Cancer ...

Vergent Bioscience has launched the Phase 3 VISUALIZE 2 trial evaluating abenacianine, a tumor-activated imaging agent designed to enhance intraoperative tumor detection in lung cancer surgery. The ...

A Nature Cell Biology study shows that vitamin B2 metabolism helps cancer cells evade ferroptosis by stabilizing ferroptosis suppressor protein-1 and sustaining antioxidant defenses. Disrupting this ...

Health and Pharma is a pioneering news and communications platform focused on health science, biotechnology, and pharmaceutical developments.

Novartis announced plans to build a fourth US radioligand therapy manufacturing facility in Winter Park, Florida, as part of its $23 billion US investment. The 35,000-square-foot, purpose-built site ...

Researchers at Mass General Brigham engineered a retargeted HSV-1 oncolytic virus that selectively infects glioblastoma cells, delivers five immunomodulators, and avoids healthy brain tissue. A single ...

A large AI-driven study of 3,476 cancer patients, presented at ESMO 2025, reveals that thymic health is strongly linked to immunotherapy success. Patients with higher thymic scores had a 35% lower ...

The Phase III SUNMO trial could mark a breakthrough for transplant-ineligible patients with relapsed or refractory large B-cell lymphoma. In this ONCOLife interview, we spoke with Dr. Jason Westin, ...

Despite two decades of clinical experience with Everolimus in transplant medicine, cancer patients continue to face preventable toxicities and fatal adverse events. While transplant patients benefit ...

The START Center for Cancer Research dosed the first U.S. patient in Moderna’s Phase 1 trial of mRNA-4106, a multivalent mRNA-based cancer vaccine targeting advanced solid tumors. The study evaluates ...

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical for advanced hepatocellular carcinoma. The therapy uses a GPC3-targeting ...

The first AI-powered companion diagnostic for non-small cell lung cancer (NSCLC) has received FDA Breakthrough Device Designation. Developed by Roche, Ventana TROP2 RxDx Device combines ...